Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Logistical requirements for autologous

Published byEvan Johns Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 Logistical requirements for autologous"— Presentation transcript:

1 Figure 2 Logistical requirements for autologous
immune or immune cell-based vaccination for glioblastoma Figure 2 | Logistical requirements for autologous immune or immune cell-based vaccination for glioblastoma. Patients undergo apheresis to enable generation of a dendritic cell-based vaccine using peptides derived from tumour-associated antigens. Multiple doses of the vaccine can be produced and used for the patient's treatment. PBMC, peripheral blood mononuclear cell. Weller, M. et al. (2017) Vaccine-based immunotherapeutic approaches to gliomas and beyond Nat. Rev. Neurol. doi: /nrneurol

Download ppt "Figure 2 Logistical requirements for autologous"

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi:10/1038/nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 4 Progression-free survival, according to treatment group

Figure 4 Progression-free survival, according to treatment group
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
Figure 2 Systemic abnormalities in AD

Figure 2 Systemic abnormalities in AD
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 4 Host damage from infection-related inflammatory

Figure 4 Host damage from infection-related inflammatory
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Figure 2 Systemic immune responses to cryptococcal antigen

Figure 2 Systemic immune responses to cryptococcal antigen
Figure 1 General framework of brain–computer interface (BCI) systems

Figure 1 General framework of brain–computer interface (BCI) systems
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Peptide vaccination using TAA-derived long peptides

Figure 2 Peptide vaccination using TAA-derived long peptides
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Proportion of patients for whom NEDA

Figure 3 Proportion of patients for whom NEDA
Figure 5 Number of AHSCT procedures for

Figure 5 Number of AHSCT procedures for
Figure 1 Outline of the AHSCT procedure

Figure 1 Outline of the AHSCT procedure

Similar presentations

Ads by Google